

GE Healthcare

Healthcare Re-imagined: Delivering the future of healthcare today

**RSNA Investor Meeting
December 1, 2005**



imagination at work



"This document contains "forward-looking statements" - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements."



imagination at work

Welcome

**RSNA Investor Meeting
December 1, 2005**



imagination at work



Today's agenda

11:00 – 11:30

Arrivals & Lunch

11:30 – 11:45

Welcome & Introduction

- Joe Hogan

11:45 – 2:00

GE Healthcare Booth Tour

2:15 – 4:00

**GE Healthcare – Winning
Today, Winning Tomorrow**

4:00 – 4:30

Q&A




imagination at work

Overall booth layout

What you'll see today...

- LightSpeed VCT – Fastest selling product in GE Healthcare's history
- PET/CT: The future of molecular imaging today
- MR: HDe, 3T and Guided Focused Ultrasound for tumor ablation
- GE Healthcare science and technology pavilion
- PACS: Industry leading image management solution



GE Healthcare: Transforming Healthcare

Bill Castell
Chairman GE
Healthcare,
Vice Chairman GE

RSNA Investor Meeting
December 1, 2005



GE Healthcare creating new markets

Technologies



Bio-Sciences



- Information Technology
- Imaging and Intervention
- Molecular Imaging
- Pharmaceutical Solutions

ONLY GE!



7
GE Healthcare

GE Healthcare's vision

At GE Healthcare, we strive to see life more clearly
We help predict, diagnose, inform and treat disease
so that every individual can live life to the fullest

From

"Late Disease"

- ✓ Physician-Centric
- ✓ Symptom Based
- ✓ Average Therapies

To

"Early Health"

- ✓ Patient-Centric
- ✓ Broad-based Diagnostics
- ✓ Specific Therapies

Healthcare Re-imagined:
Delivering clinical efficacy and
healthcare system efficiency



8
GE Healthcare

Healthcare Re-imagined Why now?

Social Drivers

- Multiple co-morbidities
- Longevity
- Expectations
- Rationing
- Costs

Technological Enablers


Physics
Biology
IT

Consumer Drivers


- Access to information
- Empowerment to define care and treatment plans
- Perception of disease as "preventable"



Transforming healthcare, creating new markets



Successful combination: One GE Healthcare



GE Healthcare: Winning Today, Winning Tomorrow

Joe Hogan,
President & CEO
GE Healthcare

RSNA Investor Meeting
December 1, 2005



imagination at work




Key messages for today

- Healthcare is a great space
- Delivering in 2005... strong 2006 outlook
- A clear vision built on a unique foundation
- Physics + Biology + IT = new age of diagnostics
- GE Healthcare to grow by improving industry efficiency and efficacy



13
GE Healthcare

Key drivers playing to GE strengths



New GE Opportunities

14
GE Healthcare

The Healthcare opportunity...

Healthcare costs

- Enormous spend - \$1.8T in US
- Admin costs = \$300B
- Shrinking population of doctors
- System cannot handle excess capacity
- Chronic care = 70% of cost

Huge markets!




Clinical efficacy

- 50% of heart failure = death (265k/yr*)
- \$32B US* healthcare spend on strokes
- Adverse drug events = 770K US deaths or injuries / year**
- 9 people / 100 unintended infection




*American Heart Association, 2004
 **Reducing and Preventing Adverse Drug Events To Decrease Hospital Costs. Research in Action, Issue 1. AHRQ Publication Number 01-0020, March 2001. Agency for Healthcare Research and Quality, Rockville, MD




Strong global growth

Regional Sales Mix



- ~45% revenues from outside the US
- Japan back on track
- Robust growth in Europe
- Broad geographic success for new products ... VCT
- Emerging markets growing strong double digit

Emerging Markets



- Huge markets ... growing double-digit
- One GE ... Enterprise and country management
- Creative solutions ... financing, infrastructure
- 2X localization
- Driving low cost country savings in sourcing, manufacturing, engineering
- Value products

GE Healthcare 2005... delivering

Strategic Goals

Accomplishments

Leading Healthcare IT

- ✓ Leading in EMR: Pending IDX acquisition
- ✓ Partnership with Intermountain Healthcare

Broad Geographic success

- ✓ Strong double digits growth in India, SEA, MEA
- ✓ Japan back on track ... ↑15%

Winning with customers

- ✓ Net Promoter Score implementation


Services growth strategy

Broadest Services Capability



- Full customer productivity engagements
- Total outsourcing
- Performance management
- Customer renewals and clinical IT
- Long-term customized agreements, focus on digital and remote
- Demand service - labor and parts

Services growth






Net Promoter Score ... Driving growth

The Premise

The best way to grow a business is to get customers to **come back for more** and **tell their friends**

- A satisfied customer tells 3 others to purchase
- A dissatisfied customer tells 9 others NOT to purchase
- It takes 12x to win back a dissatisfied customer

So we asked our customers a simple question

9-10 Promoter	
7-8 Neutral	
0-6 Detractor	

"How likely are you to recommend GE Healthcare to a friend or colleague on a scale of 0-10?"

% Promoters - % Detractors
= Net Promoter Score (NPS)

What We've Learned


- A great service business is critical to drive NPS
- There is a strong correlation of higher repurchase rates with promoters (20 point difference)
- NPS metric drives employee customer focus

What We're Doing


- Realigned field and quality resources
- Monthly op mechanisms / dashboards
- Incentive comp tied to NPS
- Driving a customer loyalty culture throughout GE Healthcare

21
GE Healthcare

Molecular medicine: The right next step



GE Healthcare ... Momentum for 2006



- Stronger, more balanced GE Healthcare portfolio
- Leading position in Healthcare IT
- Faster growth through disease focus
- Scale and strong growth in emerging markets
- Strong global footprint
- Unmatched Services capability
- Delivering clinical efficacy and healthcare system efficiency

Today's speakers

Bill Clarke, Chief Technology & Medical Officer,
GE Healthcare

Vishal Wanchoo, President & CEO, GE Healthcare IT

Reinaldo Garcia, President & CEO, GE Healthcare
Diagnostic Imaging

Peter Loescher, President & CEO, GE Healthcare
Bio-Sciences

Omar Ishrak, President & CEO, GE Healthcare
Clinical Systems

GE Healthcare: Delivering the Future of Patient Care Today

Bill Clarke
Chief Technology
& Medical Officer

RSNA Investor Meeting
December 1, 2005



imagination at work



Key messages

- Technology needs to be focused on clinical outcomes and better economics
- Because of our breadth GE Healthcare is best positioned to deliver
- We have real scale to make a difference... \$1B+ in R&D



imagination at work

GE Healthcare Focused \$1B R&D

Application Cardiology



Breakthrough

Cardiac VCT CTA
EP Ablation

Customer Value

Non-invasive diagnosis
Procedure efficiency

Oncology



DVMR
¹³C Hyperpolarized MR
Breast Cancer

Speed & ease of use
Predictive screening
Disease management

Neurology



Alzheimer's / Neurology

Diagnosis and therapy management

General Medicine

'Ultrasound Stethoscope'
Value Products

New primary diagnostic for physicians
Local solutions

Services & Enablers




EMR
Carestations ®
Cell Separations
Hospital Productivity
Chronic Disease Monitoring

Increase productivity
Reduce errors
Enabling a new generation of therapeutics
Enabling quality↑ ... cost↓
Integrated care delivery

The Healthcare challenge: Obesity trends* among US adults


(*BMI ≥30, or ~ 30lbs overweight for 5' 4" woman)



□ No Data ■ <10% ■ 10%-14% ■ 15%-19% ■ ≥20 ■ ≥25%

Source: Behavioral Risk Factor Surveillance System, CDC.

1,000,000,000 people are already overweight




- Diabetes set to double in 10 years, stroke and heart disease will rise as a result
- **80%** of diabetics will die from cardiovascular disease
- **2-4X** increase in development of coronary artery disease

Identifying high-risk diabetic patients is problematic

- Often asymptomatic
- Advanced disease at presentation

Clinical and health economic benefit as applied to coronary artery disease

The Challenge: Find & treat high risk, asymptomatic patients



Ubiquitous ultrasound in primary care


Ultrasound for Every Physician



- Readily available
- In primary care practice
- Non-invasive
- High-specificity
- Easy to read

Tomorrow's Stethoscope

Carotid Arteries



Normal

Diseased



10lbs
\$50K




2lbs
\$ Cheaper




31
GE Healthcare

Clinical and health economic benefit as applied to coronary artery disease

The Challenge: Find & treat high risk, asymptomatic patients



Biology + Physics = New age of cardiology diagnostics



Invasive: Cathlab

- \$1500+
- Low but real risk
- Labor intensive




Non-invasive: VCT

- \$500 cost
- 100% non-invasive
- GE total package VCT & Visipaque*

"For the first time, physicians are able to non-invasively diagnose heart disease in at-risk patients."
 - *Stanley Katz* - Chief of Cardiology North Shore University Hospital, NY

* Combination claim not FDA approved

Better patient outcomes and better value through integrated approach to coronary artery disease



GE Healthcare Focused \$1B R&D

Application

Cardiology



Breakthrough

Cardiac VCT CTA

EP Ablation

Customer Value

Non-invasive diagnosis

Procedure efficiency

Oncology



DVMR

¹³C Hyperpolarized MR

Breast Cancer

Speed & ease of use

Predictive screening

Disease management

Neurology



Alzheimer's / Neurology

Diagnosis and therapy management

General

Medicine

'Ultrasound Stethoscope'

Value Products

New primary diagnostic for physicians

Local solutions

Services & Enablers



EMR

Carestations ®

Cell Separations

Hospital Productivity

Chronic Disease Monitoring

Increase productivity

Reduce errors

Enabling a new generation of therapeutics

Enabling quality↑ ... cost↓

Integrated care delivery

35
GE Healthcare

GE Healthcare: Transforming Clinical Practice Through IT

Vishal Wanchoo

President IT

RSNA Investor Meeting
December 1, 2005



imagination at work



Key messages

- IT is critical for improved clinical efficacy and lower healthcare costs
- \$40+B segment is growing at double-digit rate
- GE has the full suite of products and services and is #1 in the space
- GE is well positioned for strong growth



Healthcare IT is "HOT"



IT's all about ...

- Quality
- Safety
- Workflow

**\$40B+
in 2005**

IT's all driven by ...

- Growth in outpatient services
- National programs - UK, Canada
- Pay for Performance
- Continuity of care

IT's a growth opportunity ...

- EHR in < 20% physician offices
- #1 priority for CXOs



Why IT ... a practical example

Rosaphen 1g IV q6h x 7d

ADULT ANTIBIOTIC ASSISTANT


WBC is down: Max 24hr WBC: 14.9 - Prev.: 23.2 Temp is up: Max 24hr Temp: 39.0 - Prev.: 38.9
 Renal Function is Impaired: CrCl = 49 Cr is down: Max 24 Hour Cr: 1.4- Prev. 1.5 IBWeight: 75kg
 Antibiotic Allergies: --None reported--
 Current Antibiotics:
 1. 02/03/05 14:13 1day PIPERACILL NATAZOBACTAM NA 3-0.375G(ZOSYN), VIAL 1, Q6hrs

Radiology Findings		Examination			Completed
Aspiration		Chest 1 View			02/03/05 09:32
Identified Pathogens		Specimen, Site			Collected
None identified from Microbiology, Serology, Cytology or Pathology					
Empiric Suggestion		Dosage	Route	Interval	Comment
Imipenem		500mg	IV	*q12hr	Infuse over 1hr

Outcomes published in the New England Journal of Medicine

	None	IT Assistant	
Hours of Antibiotic Therapy	330	103	↓70%
Days in hospital	17	10	↓40%
Costs for Hospital	\$44K	\$26K	↓ 40%

Information improving patient care



- ✓ Enhanced Collaboration
- ✓ Real-time Connectivity
- ✓ Improved Workflow
- ✓ Embedded Clinical Knowledge

GE Healthcare's position



Clinical Enterprise	CIS	Advanced Clinical/EMR	<ul style="list-style-type: none"> Decision support Clinical documentation 	✓	#1 IDN Partnership
		Clinical Data Repository	<ul style="list-style-type: none"> Clinical data repository Results reporting 	✓	900 Hospitals, clinics ~80% rev. visibility
Departmental		Departmental	<ul style="list-style-type: none"> PACS, AW, Cardiology Perinatal, Perioperative Emergency Dept, ICU 	✓	#1 PACS share #1 Perinatal footprint ⁽¹⁾
		Ancillary Clinical	<ul style="list-style-type: none"> Lab Pharmacy Radiology IS 	✓	#1 rated Pharmacy ⁽²⁾ 10 "Top" Hospitals
Administrative Enterprise		Patient Management	<ul style="list-style-type: none"> Patient registration Billing, Scheduling 	✓	#2 rated patient access ⁽¹⁾ & financials
	HIS	Financial System	<ul style="list-style-type: none"> A/P, A/R, Payroll General ledger 	✓	Robust interfaces & partnerships
Physician Office		EMR	<ul style="list-style-type: none"> Clinical documentation Decision support 	✓	~20% CAGR
		Practice Management	<ul style="list-style-type: none"> Scheduling Billing 	✓	~200,000 physicians

(1) KLAS 2005 Mid-year report
(2) US News & World Report 2004 Top Hospitals

GE and Intermountain Health Care



+



=

Next Generation EMR

- 22 Hospitals / 100 Clinics
- #1 Integrated Delivery Network
- 30 years of Informatics Expertise

Contributing ...

- Intellectual Property
- Clinical Access & Know-How
- Development Resources

- 10 Clinical Department Apps
- Global Provider of HCIT

Contributing ...

- Intellectual Property
- Commercial Excellence
- People & Infrastructure

- Complete Clinical Enterprise Product
- Installed at all IHC Sites
- 2007 Commercially Viable Offering



Key messages

- IT has demonstrated better clinical outcomes and increased health system productivity
- Tremendous opportunity to increase penetration
- GE has executed on strategy and grown the business profitably
- Future growth driven by increased adoption, global penetration, customer expansion



43
GE Healthcare



GE Healthcare: Diagnostic Imaging Reinaldo Garcia President & CEO, Diagnostic Imaging

RSNA Investor Meeting
December 1, 2005



Diagnostic Imaging: Changing how clinicians look at disease


An increasingly important part of the Doctor's "bag"

- Need for improved outcomes driving growth in procedures
- Technological breakthroughs transforming imaging
- Combined GE Healthcare science/technology creating growth opportunities
- Imaging being used by Pharma to accelerate drug development



45
GE Healthcare

Healthcare Trends Drive Imaging Growth




Sources: US Census Bureau, Economist Intelligence Unit, Medistat, Datamonitor

DI: Strong global growth opportunity

\$2.5B of Organic Growth

Product Breadth



CT

New LightSpeed VCT

- \$300MM in cardiology growth

Nuclear Medicine/PET

PET/CT...platform integration + Bio-Sciences

Oncology penetration... cardio & neuro next

MR

#1 share position

High Definition MR, 3T leadership

- Double-digit procedure growth

X-ray

Digital Transformation...3D Tomo

Vascular X-ray share +20 points

Digital installed base 2X nearest competitor



imagination at work


Driving Clinical Efficacy

47
GE Healthcare

Clinically-driven development



+




+



LightSpeed VCT

CT

- Robust, non-invasive diagnostic exam of coronary arteries



PET/CT

- Enhanced lesion detectability
- Radiation therapy planning
- Workflow efficiency




Discovery STE



MR

- Brain surgery planning
- Stroke treatment decisions
- Patient movement problems




Signa HDx



Mammography

- Improved cancer detection




Senographe




Functional imaging with PET/CT enabling improvements in cancer care

Annual Industry Oncology PET/CT Procedures




GE Healthcare Global PET/CT Revenue



Discovery ST & STE

- Industry's highest sensitivity, improving lesion detectability
- Multiple acquisition modes (2D/3D) to image all patients
- Motion management (4D) optimizing radiation treatment planning
- First fully integrated PET/CT workflow via the Discovery Dimension Console



New MR applications drive growth

Unmet Clinical Needs ...

Orthopedics... Cartilage Osteoarthritis

- 400,000 total joint replacements per year (US)

Body... Quantification of fatty liver disease

- 1 in 2 cancers arise from Abdomen and pelvis 40% mortality (US 2004 ~580,000+ cases)

Cardiovascular... Diabetes


- 18.2MM (6.3%) people in US have diabetes... Angiography of lower legs required pre-amputation

Neuro... Pre-surgical planning


- 1 in 5 brain tumor resections results in post-op deficit... Cortical mapping is invasive and time consuming

... Clinical Application Roadmap


Cartilage Quantification Package




Plaque Characterization



Complete Oncology Screen in 6 Breath Holds




Volumetric Stroke Assessment



Neurosurgical Planning Suite




Signa product Line expansion addresses breadth of market segments




Transforming breast care

Only 8% of US sites are digital today...



... clinical data accelerating the transformation

"Digital mammography demonstrates improved cancer detection for important subsets of patients" *ACRIN Study*



Senographe Digital Mammography

- Imagination Breakthrough..... transforming breast care diagnosis
- Proven GE detector technology
- Clinically proven reduced recall rate
- Expanding clinical capabilities (eg, tomosynthesis)
- Addressing key provider economic challenges



Cardiac imaging capabilities driving fastest selling product in GE Healthcare history



Summary: Global growth opportunity

Imaging Growth Drivers

Global demographic and healthcare trends

Demand for technological innovation / Clinical efficacy

Expanding role of imaging in diagnosis and treatment of disease

Why GE?

- Strong technology portfolio
- Integrated DI and Medical Diagnostics product roadmaps
- Ongoing R&D investment
- Broad product portfolio addresses global clinical and economic needs
- Global distribution coverage
- Global product development
- Disease focus and clinical trials
- Commercializing new imaging applications (eg, MR guided focused Ultrasound)



GE Healthcare: Diagnostics to Transform Patient Care

Peter Loescher
President & CEO
Bio-Sciences

RSNA Investor Meeting
December 1, 2005




imagination at work



Bio-Sciences: Two world-leading businesses

Revenues in \$B


Medical Diagnostics:
• Contrast agents and radiopharmaceuticals



Life Sciences:
• Tools for BioRx manufacture and drug discovery


Growth Engine Life Sciences

Huge opportunity for GE expansion



BioProcess Opportunity Growing

- Increasing Biopharmaceuticals
- GE FDA manufacturing secures 90%



Medical Diagnostics key messages

- Gold-standard products growing at 20%+
- Disease integration with DI
- Successful life cycle management
- Clinical differentiation driving growth
- Pharma deals for tandem Rx and Dx development




Medical Diagnostics: Global leadership, synergy with DI

Modality	X-ray/CT	MR	Nuclear Medicine
Key Brands	Visipaque Omnipaque	Omniscan	Myoview DatSCAN
Global Position	#1	#2	#1

Key Drivers

- Payors want better outcomes
- Shift to less invasive, outpatient procedures
- Growth in interventional solutions


Medical Diagnostics Revenues



Business Advantages

- Multiple modalities across key disease areas
- Patented products growing 20%+
- Synergy with GE Healthcare DI
- New indications/premium pricing

Spanning anatomical to functional images




Proving growth via clinical validation



ISOSMOLAR
VISIPAQUE™
(IODIXANOL) INJECTION


- *New England Journal Medicine* data: February 2003
- Premium pricing
- First choice for renal-compromised patients
- Expanding patient pool
- Evaluating for cardiology indications with the VCT

34% CAGR
since 2002



Cardio focus: Medical Diagnostics for each stage of detection

Disease State	Mild (Asymptomatic)	Moderate (Symptomatic)	Severe (CHF)
Prognostic Data	Pre-test probability Risk factors Calcium Score	Cardiac Function Perfusion & Viability Coronary anatomy	Biopsy Viability Innervation
Physician	General Practice Family Practice Internal Medicine	Cardiologist Echocardiographer, Nuclear Interventional	Cardiac Surgeon
GE Product Fit	Vulnerable Plaque SPECT Myoview (Dual Isotope) CZT SPECT Visipaque VCT	Optison U/S Myoview SPECT Thallium-201 SPECT Visipaque Cath Omnipaque Cath	
Therapy	Medical Statins Behavior modification	Non-surgical Intervention PTCA CABG Stenting	Surgical ICD Transplantation




One GE Healthcare

Standardizing PET tracer production for new diagnostics

Strong Clinical Needs

(K) Global Incidence of Major Tumor Types



Source: WHO Globalscan

Functional/Disease-Specific Imaging

- FastLab/FDG ... Universal PET chemistry ... Launch 4Q 2006
- Launch platform for proprietary GE PET tracers
 - Cancer: Angiogenesis
 - Neurology: Alzheimer's




- Future ... Metabolic, disease-specific agents ... Proteins, Genes, Receptors
- Molecular pathology integration

GE Engineering + Bio-Sciences chemistry

Neurology: Next \$1B imaging market


Creating a market in Parkinson's Disease

Clinical Need




Driving the DaTSCAN* Clinical Program

- Parkinson's often misdiagnosed as essential tremors
- DaTSCAN images dopamine transporters in brain...sensitivity differentiates diagnosis
- DaTSCAN results in fewer patients treated with inappropriate therapy
- DaTSCAN growth in Europe \$20MM in 2 years
- Pursuing Parkinson's product in US




Normal Patient



Late stage PS

2004 Weekly DaTSCAN Sales in Belgium



*Source: Health Economic Research Project, "An assessment of the cost-effectiveness of DaTSCAN SPECT for the diagnosis of patients with clinically uncertain Parkinsonism." Approved in EU only.

Pharmaceutical enterprise: Driving smarter drug development



Diagnostic-Therapeutic Intersection

\$80B R&D spend



Therapy Monitoring Alzheimer's

Addressing Pharma's bottlenecks with Advanced Imaging, IT & Pharmacogenomics



Complementary Channels Advanced Clinical IT Imaging

GE breadth of sales, service, support, financing, marketing & IT to any Pharma customer



Leadership Products & Services



Medical Diagnostics: Essentials in place for growth

- Gold-standard products growing at 20%+
- Disease integration with DI
- Successful life cycle management
- Clinical differentiation driving growth
- Pharma deals for tandem Rx and Dx development



65
GE Healthcare

Clinical Systems: Technologies for Every Patient

Omar Ishrak
President & CEO
Clinical Systems

RSNA Investor Meeting
December 1, 2005



What we'll cover...

- Business Overview... a unique collection of market leaders
- Clinical Systems... positioning in a dynamic environment
- Ultrasound... shaping ultrasound's role in healthcare
- Extending Growth Strategies
 - Monitoring... lead through NPI
 - Technology Convergence... leveraging breadth
 - Value Products... strategy for global leadership



Clinical Systems overview

\$3.4B
12% CAGR



Ultrasound



Monitoring



Specialties



Services

	Ultrasound	Monitoring	Specialties	Services
Mkt (\$B)	\$3.9	\$2.8	\$2.7	\$3.6
2005 Rev V%	13	7	11	5
GE Position	#1	#1	#1	--

- High "patient-touch"
- Ubiquitous technologies
- Spans the continuum of care
- Successful acquisitions → growth platforms

Growth Strategies

Innovation



Ubiquitous




Convergence



The big picture


One cardiac patient... 10-day hospital stay...
Six departments... 105 healthcare professionals




From screening to therapy, Clinical Systems
can make a difference in William Webb's care

LIFE magazine

Growth in a dynamic environment




Ultrasound history of growth



71

GE Healthcare


Innovation: Volume ultrasound



72


GE Healthcare

Ubiquitous ultrasound shapes the future




Monitoring for every patient


Life critical technologies serving every care area



Convergence: Re-defining anesthesia



Ubiquitous products fuel global growth



In summary...

- A unique collection of market leaders
- Positioned for growth in a dynamic environment
- Shaping ultrasound's role in healthcare
- Monitoring leadership through annual NPI
- Leveraging breadth of expertise for technology fusion
- Clear strategy for global leadership in value segments



**GE Healthcare
Summary**

GE Healthcare's vision

At GE Healthcare, we strive to see life more clearly
We help predict, diagnose, inform and treat disease
so that every individual can live life to the fullest

From

"Late Disease"

- ✓ Physician-Centric
- ✓ Symptom Based
- ✓ Average Therapies

To

"Early Health"

- ✓ Patient-Centric
- ✓ Broad-based Diagnostics
- ✓ Specific Therapies


Healthcare Re-imagined:
Delivering clinical efficacy and
healthcare system efficiency



79
GE Healthcare


Only GE Healthcare

- The only wing to wing diagnostics company
- Clear Leader in Medical Diagnostics, Diagnostic Imaging, Healthcare IT, Services, Clinical Systems, Protein Separations
- Uniquely capable of delivering clinical outcomes and better healthcare economics
- Real scale... R&D \$1B+, global reach, broadest distribution
- Great integration success...more to come



Healthcare Re-imagined

GE Healthcare ... Momentum for 2006



- Stronger, more balanced GE Healthcare portfolio
- Leading position in Healthcare IT
- Faster growth through disease focus
- Scale and strong growth in emerging markets
- Strong global footprint
- Unmatched Services capability
- Delivering clinical efficacy and healthcare system efficiency



imagination at work